Systematic Review/Meta-analysis

Risk Factors for Hospital Readmission Post-Transcatheter Aortic Valve Implantation in the Contemporary Era: A Systematic Review

Raumil V. Patel, MSc,a,b Mithunan Ravindran, MD,a Ragavie Manoragavan, BSc,c Abi Sriharan, MSc, DPhil, b and Harindra C. Wijeysundera, MD, PhDb,c,d,e

a Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
b Institute for Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada
c Division of Cardiology, Department of Medicine, Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
d Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
e Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada

ABSTRACT

Background: Despite transcatheter aortic valve implantation (TAVI) becoming a widely accepted therapeutic option for the management of aortic stenosis, post-procedure readmission rates remain high. Rehospitalization is associated with negative patient outcomes, as well as increased healthcare costs, and has therefore been identified as an important target for quality improvement. Strategies to reduce the post-TAVI readmission rate are needed but require the identification of the key risk factors.

The prevalence of aortic stenosis, the most common form of valvular heart disease, is expected to grow significantly as the population ages, representing a major challenge to healthcare systems around the world. In Canada, transcatheter aortic valve implantation (TAVI) has become the standard of care for inoperable or high-surgical-risk patients with symptomatic severe aortic stenosis, with more recent evidence supporting use of TAVI as a reasonable alternative in intermediate- and low-risk patients. Despite the dramatic improvements in the safety and efficacy of TAVI, post-procedure early and late readmissions remain a concern. Recent studies have reported that up to 22.4% and 54.3% of patients are readmitted at 30 days and 1 year after TAVI, respectively.

Preventing avoidable rehospitalizations has emerged as an important quality-improvement initiative, with policies such as the Hospital Readmissions Reduction Program in the US offering financial incentives to minimize unnecessary hospitalizations.

In TAVI, both cardiac and noncardiac causes have been identified as important contributors. Rehospitalization has been associated with an increase in all-cause mortality and healthcare costs. Reducing readmission rates requires a rigorous means of identifying patients at high risk for readmission. Accordingly, in this systematic review, we aim to summarize the current evidence on predictors of post-procedure readmission in patients with aortic stenosis eligible for TAVI, with the goal of identifying pre-procedural comorbidities, as well as potentially modifiable periprocedural predictors. This identification in turn would facilitate interventions to reduce readmissions, which would need to be independently tested.

Methods

Protocol and registration

Our systematic review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, and registered with the
Patients at high risk for rehospitalization. Our systematic review aims to identify predictors of post-procedure readmission in patients eligible for TAVI.

Methods: We conducted a comprehensive search of the MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) databases for the time period from 2015 to the present for articles evaluating risk factors for rehospitalization post-TAVI with a follow-up period of at least 30 days in adults age ≥ 70 years with aortic stenosis. The quality of included studies was evaluated using the Newcastle-Ottawa Scale. We present the results as a qualitative narrative review.

Results: We identified 49 studies involving 828,528 patients. Post-TAVI readmission is frequent, and rates vary (14.9% to 54.3% at 1 year). The most-frequent predictors identified for both 30-day and 1-year post-TAVI readmission are atrial fibrillation, lung disease, renal disease, diabetes mellitus, in-hospital life-threatening bleeding, and non-femoral access.

Conclusions: This systematic review identifies the most-common predictors for 30-day and 1-year readmission post-TAVI, including comorbidities and potentially modifiable procedural approaches and complications. These predictors can be used to identify patients at high-risk for readmission who are most likely to benefit from increased support and follow-up post-TAVI.

International Prospective Register of Systematic Reviews (PROSPERO: CRD42021244168).

Eligibility criteria

We included randomized controlled trials (RCTs), observational cohort studies, and retrospective case-control studies of adults (age ≥ 70 years) with aortic stenosis eligible for TAVI. We excluded studies in which the primary intervention was surgical aortic valve replacement or valve-in-valve TAVI.

To be included, a study had to evaluate one or more risk factors for rehospitalization post-TAVI, with a follow-up period of at least 30 days. Our primary outcome of interest is risk factors for early (at < 30 days) and late (at ≥ 30 days) all-cause readmission post-TAVI, and secondary outcomes include cardiac vs noncardiac causes of both early and late hospital readmission rates, as well as all-cause mortality in readmitted patients.

We excluded case reports, conference abstracts, and review articles. We included only studies written in the English language, and only those published in 2015 or later, as this period saw the expansion of TAVI to intermediate- and low-risk patients.

Information sources

The databases, platforms, and coverage were MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL), from 2015 to present.

Search strategy

The search strategy was developed by a medical librarian in consultation with a study investigator (R.P.). An exploratory literature review was conducted to find relevant articles, to mine key words. The search strategy was formed based on the following key words: “transcatheter aortic valve implantation,” “transcatheter aortic valve replacement,” “readmission,” and “rehospitalization.” The following medical subject heading (MeSH) terms were explored: “transcatheter aortic valve replacement,” “heart valve prosthesis implantation,” “patient readmission,” and “hospital readmission.” The full search strategies are available in Supplemental Table S1.

Selection process

After de-duplication of search results, 2 independent investigators (R.P. and M.R.) used predefined inclusion and exclusion criteria to review titles and abstracts. Afterward, the full texts of eligible studies were reviewed for inclusion by 2 independent investigators (R.P. and M.R.). Throughout the screening process, all disagreements were resolved via consensus or via a third investigator (H.W.) when consensus could not be reached. De-duplication, screening, and data abstraction were performed using the Web-based Covidence software (Veritas Health Innovation, Melbourne, Australia).11

Data collection process

We prepared a data extraction form on Covidence, and 2 independent investigators (R.P. and M.R.) carried out data
extraction from eligible studies. The 2 investigators met to identify and resolve discrepancies through discussion. Please see Supplemental Table S2 for data elements.

Variables

In studies for which both univariate and multivariable analyses were performed to determine predictors for readmission, we included only predictors that were statistically significant in the multivariable analysis. We categorized predictors for early and late hospital readmission into 7 categories: (i) demographic factor; (ii) clinical characteristic; (iii) cardiac comorbidity or previous intervention; (iv) medical comorbidity; (v) laboratory marker; (vi) procedural characteristic; and (vii) procedural complication. Cardiac causes were those pathologies that are intrinsic to the heart, such as arrhythmia or heart failure, whereas noncardiac causes were all other medical comorbidities, such as lung or renal pathology. Procedural characteristics and complications were considered to be potentially modifiable. The Elixhauser Comorbidity Index quantifies a patient’s comorbidity based on 30 International Classification of Diseases (ICD), ninth revision, Clinical Modification and ICD, tenth revision diagnosis codes, which are weighted based on the association of each comorbidity with death, to produce a summary index.12

Study quality assessment

Two authors (R.P. and M.R) independently evaluated study quality using the Newcastle-Ottawa Scale, and discrepancies were resolved by discussion. The quality assessment is presented in Supplemental Table S3.

Statistical analysis

We extracted the absolute number of events when it was available, or calculated it based on the statistical measures reported. Given the substantial heterogeneity among the included studies in the statistical measures used to report outcome data, a meta-analysis was not performed.

Results

Study selection (flow of studies)

Figure 1 illustrates the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram for study selection. Database searching retrieved 1566 records, of which 413 were duplicates. We excluded 919 records after title and abstract screening, and assessed the full texts of 231 records. Ultimately, we included 49 studies in the review.

Study characteristics

Study characteristics are summarized in Table 1. The design of all included studies was either cohort (45) or RCT (4), and all were published between 2015 and 2022. The study period for included studies ranged from 1 to 10 years. Seventeen of the included studies were reports on early hospitalizations, 21 were reports on late hospitalizations, and 11 were reports on both. The definitions of early and late follow-up periods were similar across studies. Across all included studies, 828,528 patients underwent TAVI, and sample sizes ranged from 63 to 171,361 patients. The percentage of female patients ranged from 27% to 69.8% across studies. Study patients were older adults (age 74-84 years). Only 18 studies reported baseline surgical risk. Most patients were at intermediate or significant risk for in-hospital mortality and morbidity. The Society of Thoracic Surgeons (STS) score, the European System for Cardiac Operative Risk Evaluation (EuroSCORE), and the EuroSCORE II ranged from 3.2% to 10%, 13.3% to 23%, and 0.07% to 5.9%, respectively. Of the 15 studies reporting access site, the transfemoral approach was most frequently used, with the percentage of patients having a transfemoral TAVI ranging from 45% to 97.4%. The type of valve used was reported by 13 studies. Balloon-expandable valves were most common (6% to 100%), followed by self-expandable valves (0% to 90%).

Readmission rates

Only 17 of the 49 included studies reported readmission rate data (Table 2). Readmission rates were divided into 3 categories—early and late—and 3 subcategories—all-cause, cardiac cause, and noncardiac cause. Post-TAVI readmission rates are variable but high. All-cause early readmission rates range from 3.5% to 22.4%, and all-cause late readmission rates range from 14.9% to 54.3%. Despite the variability in rehospitalization rates, the causes of hospital readmission are consistent. Noncardiac causes are more common than cardiac causes for readmission. Cardiac causes were responsible for 31.8% to 44.6% of early readmissions, and 32% to 53.7% of late readmissions. Noncardiac causes were responsible for 55.4% to 68.2% of early readmissions, and 46.3% to 68% of late readmissions. The most common noncardiac causes are respiratory and bleeding events, and infection.5,8,13,14 The most common cardiac causes for readmission are heart failure and arrhythmia.5,8,13,15

Mortality rates

Eight studies (35,552 patients) reported the all-cause mortality rate, which ranged from 1.1% to 44.4%, with the mean follow-up duration ranging from 1 to 32 months (Table 3). Four studies (14,794 patients) reported mortality rate in readmitted patients, and 2 studies (1859 patients) reported mortality rate in non-readmitted patients. The mortality rate in readmitted patients was higher (30.2%), compared with that in patients without hospital readmission (19.2%). Multiple studies reported a statistically significant increase in all-cause mortality in readmitted patients, compared with that in patients who were not readmitted.5,10,17 Mortality risk also correlated with number of hospital readmissions and time of readmission. Patients with multiple hospital readmissions or a late readmission were at higher risk for mortality compared to patients with a single or early readmission.16,17

Predictors for early hospital readmission

Of the 49 included studies, 18 assessed risk factors for early hospital readmission post-TAVI. In Figure 2, we summarize the most frequently identified predictors for early readmission, and a list of all identified predictors can be found in Supplemental Table S4. A total of 37 unique predictors were identified among the 18 studies. Across the 37 predictors, the
most-reported risk factor was atrial fibrillation/flutter (5 studies; 55,085 patients). The next most common predictors (4 studies each) were discharge to a skilled nursing facility (68,282 patients), chronic lung disease (39,595 patients), and non-femoral access (38,620 patients). The next most reported risk factors were as follows: diabetes mellitus (3 studies; 34,615 patients); in-hospital life-threatening bleeding, vascular complication, or transfusion (3 studies; 66,543 patients); and more than 4 Elixhauser comorbidities (2 studies; 12,562 patients). Taken together, renal pathologies (acute kidney injury, chronic kidney disease, and renal failure) were identified by 10 studies (96,625 patients) as risk factors for readmission post-TAVI. In the demographic factors category, the most identified risk factor for readmission was increasing age (3 studies; 74,814 patients). For laboratory markers, 2 studies (1434 patients) found an association between hemoglobin level and rehospitalization risk. A low hemoglobin level at discharge increased risk for readmission, whereas a high preoperative hemoglobin level was protective against readmission.

Predictors for late hospital readmission

Of the 49 included studies, 34 identified risk factors for late hospital readmission post-TAVI. Figure 2 depicts the most frequently identified predictors for late readmission, and a list of all identified predictors can be found in Supplemental Table S5. Across the 34 studies, a total of 59 unique predictors were reported. The predictor most frequently identified by the included studies was atrial fibrillation (11 studies; 157,601 patients)—both pre-existing and new-onset atrial fibrillation. Other cardiac risk factors included heart failure (5 studies; 79,563 patients) and post-TAVI aortic and pre-TAVI mitral regurgitation (4 studies; 37,408 patients). Among the medical comorbidities category, the most common predictors were those related to lung pathology (including chronic obstructive pulmonary disease, interstitial lung disease, pulmonary hypertension and chronic lung disease [7 studies; 8821 patients]), diabetes mellitus (3 studies; 75,673 patients), renal pathology (including chronic kidney injury, acute kidney injury, and stage 3 kidney injury [5 studies; 78,631 patients]), or peripheral vascular disease (3 studies; 3786 patients). Frailty (3 studies; 26,550 patients) and increased Charlson score (2 studies; 4676 patients) were the most common clinical risk factors, and in-hospital life-threatening bleeding, vascular complications, or transfusions was the most common procedural complication risk factor identified (4 studies; 76,135 patients). Increased age,
| Study | Study design | Study period, y | Follow-up period | Population size | Average age, y | Female patients | STS score | EuroScore | EuroScore II | Transfemoral access | Balloon-expandable valve | Self-expandable valve | Other valve |
|-------|--------------|-----------------|------------------|-----------------|----------------|----------------|-----------|-----------|-------------|---------------------|---------------------|---------------------|------------|
| Arai et al. 2018 | C | 3 | B | 1215 | — | — | — | — | — | — | — | — | — |
| Auffret et al. 2020 | C | 8 | B | 750 | — | — | — | — | — | 0.07 ± 0.06 | 73.4 | 53.6 | 44.2 | 2.2 |
| Czarnecki et al. 2019 | C | 6 | L | 937 | 83 (78–87) | 44.3 | — | — | — | — | — | — | — |
| Czarnecki et al. 2020 | C | 4 | B | 2547 | 83 (78–87) | 45.7 | — | — | — | — | — | — | — |
| Dzido et al. 2019 | C | 4 | E | 18,568 | 84 (79–88) | 48.6 | 6.8 (4.5–10.2) | — | — | — | — | — | — |
| Durand et al. 2017 | C | 4 | L | 546 | 83.9 ± 7.3 | 53.3 | — | 15.6 ± 10.9 | — | — | — | — | — |
| Elbaz-Green et al. 2019 | C | 4 | B | 2129 | 83 (78–87) | 45.8 | — | — | — | — | — | — | — |
| Forcillo et al. 2017 | C | 8 | B | 714 | 83 (77–87) | 46.6 | 10 (7.2–13.9) | — | — | — | — | — | — |
| Franzzone et al. 2017 | C | 7 | L | 868 | 82.4 ± 5.8 | 53.7 | 6.6 ± 4.3 | — | — | — | — | — | — |
| Gueden et al. 2019 | C | 6 | L | 1139 | 82.4 ± 7.7 | 47.8 | 4.3 ± 3.1 | — | — | — | — | — | — |
| Kote et al. 2017 | C | 1 | E | 12,221 | 81.5 ± 8.4 | 49.1 | — | — | — | — | — | — | — |
| Nobella-Franco et al. 2015 | C | - | B | 720 | 82 (77–86) | 58.2 | — | — | — | — | — | — | — |
| Panaich et al. 2016 | C | 1 | E | 5702 | — | — | — | — | — | — | — | — | — |
| Sanchez et al. 2020 | C | 2 | E | 10,345 | 81.2 ± 7.9 | 62.5 | 7.5 ± 4.9 | — | — | — | — | — | — |
| Tripathi et al. 2020 | C | 1 | L | 73,784 | — | — | — | — | — | — | — | — | — |
| Yerasi et al. 2021 | C | 4 | E | 3104 | 80.3 ± 8.4 | 39 | — | — | — | — | — | — | — |
| Doshi et al. 2019 | C | 3 | E | 54,117 | — | — | — | — | — | — | — | — | — |
| Pajjuru et al. 2022 | C | 5 | L | 171,361 | — | — | — | — | — | — | — | — | — |
| Johansson et al. 2016 | C | 6 | L | 166 | — | 23 ± 15 | — | — | — | — | — | — | — |
| Malik et al. 2020 | C | 1 | L | 20,504 | 80.6 ± 8.3 | 45.9 | — | — | — | — | — | — | — |
| Saji et al. 2018 | C | 3 | B | 155 | 85 (82–88) | 65 | 6 (4.7–8.2) | — | — | — | 74 | 91 | 8.3 | 0.7 |
| Deharo et al. 2020 | C | 10 | L | 31,113 | — | — | — | — | — | — | — | — | — |
| Ko et al. 2018 | C | 3 | L | 63 | 81.7 ± 7.6 | 47 | — | — | — | — | — | — | — |
| Aljabary et al. 2018 | C | 5 | L | 1257 | 82.3 ± 7.2 | 47.1 | — | — | — | — | — | — | — |
| Chamandi et al. 2018 | C | 8 | L | 1629 | — | — | — | — | — | — | — | — | — |
| Nazif et al. 2015 | C | 10 | L | 1973 | — | — | — | — | — | — | — | — | — |
| Jorgensen et al. 2019 | C | 10 | L | 816 | 81 (75–85) | — | 3.2 (2.2–4.9) | — | — | — | — | — | — |
| Nazif et al. 2019 | C | 5 | L | 1179 | — | — | — | — | — | — | — | — | — |
| Doshi et al. 2020 | C | 3 | E | 10,847 | 82.4 ± 7.2 | 46.4 | — | — | — | — | — | — | — |
| Mentias et al. 2019 | C | 2 | L | 72,660 | 81.9 ± 8.1 | 47 | — | — | — | — | — | — | — |
| Zweiker et al. 2017 | C | 7 | L | 398 | 82 (78–85) | 63 | 6.3 (3.8–9.6) | 13.3 (7.8–23.8) | 5.9 (3.2–10.8) | — | — | — | — |
| Shahim et al. 2021 | C | 4 | L | 948 | — | — | — | — | — | — | — | — | — |
| Hiski et al. 2017 | C | 3 | L | 1124 | 85 (82–88) | 69.8 | 6.7 (4.7–9.4) | — | — | — | — | — | — |
| Caughron et al. 2021 | C | 6 | B | 309 | 78.2 ± 10.3 | 44.3 | 5 ± 4.4 | — | — | — | — | — | — |
| Ando et al. 2020 | C | 4 | E | 5731 | 74 ± 10.1 | 38.1 | — | — | — | — | — | — | — |
| Feldman et al. 2021 | C | 3 | L | 341 | 81.4 ± 8 | 51.9 | 6.7 ± 4.8 | — | — | — | — | — | — |
| Gracia et al. 2020 | C | 3 | E | 298 | — | — | — | — | — | — | — | — | — |
| Testa et al. 2016 | C | 4 | B | 990 | — | — | — | — | — | — | — | — | — |
| Thouari et al. 2016 | C | 10 | L | 2,531 | — | — | — | — | — | — | — | — | — |
| Tirado-Conde et al. 2016 | C | 1 | L | 303 | 84 (79–87) | 63 | — | 3.62 (2.6–6) | 67 | 33 | 0 | — | — |
| O’Leary et al. 2020 | C | 8 | L | 3391 | 82 ± 7.5 | 41.9 | — | — | — | — | — | — | — |
| Lemor et al. 2019 | C | 3 | E | 36,269 | 81.3 ± 8.5 | 47.9 | — | — | — | — | — | — | — |
| Inohara et al. 2018 | C | 2 | L | 21,312 | — | — | — | — | — | — | — | — | — |
| Hermann et al. 2018 | C | 3 | L | 62,125 | 82 (76–87) | 46.3 | 6 (3.9–9.3) | — | — | — | — | — | — |
| Emami et al. 2020 | C | 5 | E | 105,603 | — | — | — | — | — | — | — | — | — |
| Arora et al. 2020 | C | 5 | E | 47,255 | — | — | — | — | — | — | — | — | — |
| Freitas-Ferraz et al. 2020 | C | 6 | L | 308 | 80.5 ± 7.2 | 27 | 7.7 (5.3–11.9) | — | — | — | — | — | — |
| McCarthy et al. 2018 | C | 4 | B | 34,576 | — | — | — | — | — | — | — | — | — |
| Miuara et al. 2020 | C | 3 | L | 1587 | — | — | — | — | — | — | — | — | — |

Values are %, unless otherwise indicated.

B, both; C, cohort; E, early; EuroSCORE, European System for Cardiac Operative Risk Evaluation; L, late; RCT, randomized controlled trial; STS, Society of Thoracic Surgeons.

* Calculated from study data.
Table 2. Early and late readmission rates post-transcatheter aortic valve implantation

| Study                  | All-cause | Cardiac cause | Noncardiac cause | All-cause | Cardiac cause | Noncardiac cause |
|------------------------|-----------|---------------|------------------|-----------|---------------|------------------|
| Arai et al. 201813     | 42/1215   | 18/42         | 24/42            | 181/1215  | 59/181        | 122/181          |
| Affr et al. 202016     | 301/750   | 138/301       | 182/301          | 301/750   | 138/301       | 182/301          |
| Czarnecki et al. 201915| 462/937   | 269/937       | 193/937          | 628/924   | 303/924       | 325/924          |
| Czarnecki et al. 2020  | 147/547   | 72/547        | 75/547           | 166/580   | 84/580        | 82/580           |
| Forcillo et al. 2017   | 74/714    | 41/714        | 33/714           | 221/868   | 140/868       | 81/868           |
| Franzone et al. 2017   | 37/74     | 19/74         | 18/74            | 39/79     | 20/79         | 19/79            |
| Guedeney et al. 2019   | 2188/12,221 | 836/2188 | 1352/2188         | 232/861   | 132/861       | 100/861          |
| Kolte et al. 2017      | 115/720   | 49/115        | 66/115           | 391/720   | 159/720       | 232/720          |
| Nombela-Franco et al. 2015 | 1215/5433 | 439/1215 | 776/1215          | 16,343/73,784 | 5294/16,343 | 10,419/16,343  |
| Panaich et al. 2015    | 950/10,345 | 417/950 | 533/950            | 2,193/25,000 | 1,154/25,000 | 939/25,000     |
| Sanchez et al. 2020   | 269/3104  | 221/3104      | 48/3104          | 2,193/25,000 | 1,154/25,000 | 939/25,000     |
| Tripathi et al. 2020   | 4532/54,117 | 524/4532 | 401/4532          | 10,419/16,343 | 5294/16,343 | 10,419/16,343  |

Values are n/N (%), unless otherwise indicated.
* Calculated from study data.
1 Study reported a median 30-day readmission rate.

Discussion

The purpose of this systematic review was to identify predictors of both early and late readmission post-TAVI. Our main findings are as follows: (i) post-TAVI readmission is common and has both cardiac and noncardiac causes; (ii) a possible association exists between post-TAVI readmission and subsequent mortality, requiring further investigation; and (iii) several comorbidities and procedural variables predict post-TAVI readmission with significant overlap between predictors for early and late readmission.

These findings highlight the importance of identifying patients most at risk for post-TAVI readmission, whereas Doshi et al. (2019)24 found female sex and male sex, anemia, nonfemoral access, and discharge to a skilled nursing facility remained predictors for readmission. Similarly, multiple studies have shown that nonagenarians and pre-procedure mitral regurgitation, diabetes mellitus, and pre-procedure systolic dysfunction are predictors for several predictors, such as hospital length of stay and overall mortality, and are associated with increased risk for mortality in TAVI patients with a post-procedure aortic regurgitation. Czarnecki et al. (2016)25 found a total of 15 unique predictors. Both of these findings highlight the importance of identifying patients most at risk for readmission.
have a risk level for post-procedure readmission similar to that of a younger population. Moreover, we found one study that revealed an association of balloon-expanding valves with a decrease in readmission risk, compared with the risk with self-expanding valves, but this association was not found in the Comparison of Balloon-Expandable vs Self-expandable Valves in Patients Undergoing Transcatheter Aortic Valve Replacement (CHOICE) 25 and Repositionable Percutaneous Replacement of Stenotic Aortic Valve Through Implantation of Lotus Valve System—Randomized Clinical Evaluation (REPRISE III) 26 RCTs. In addition, we found evidence for increased readmission risk in patients requiring pacemaker implantation, but once more, this association was not seen in the REPRISE III RCT. 26 Given the large number of studies, we believe the value of our work is in summarizing the breadth of the literature and identifying those risk factors for which the findings show broad consistency.

Our findings have significant implications with respect to post-TAVI readmission rates. By identifying common predictors for early and late post-procedure readmission, our work can inform risk stratification. This benefit will aid both primary care physicians and interdisciplinary TAVI teams,

Table 3. All-cause mortality rate, and mortality rate in readmitted and non-readmitted patients post-transcatheter aortic valve implantation

| Study                  | Mean follow-up period, mo | All-cause mortality rate | Mortality rate in readmitted patients | Mortality rate in non-readmitted patients |
|------------------------|---------------------------|--------------------------|---------------------------------------|------------------------------------------|
| Auffret et al. 2020 16 | 32                        | 333/750 (44.4)           | —                                     | —                                         |
| Czarnecki et al. 2019 28 | 12                       | 126/937 (13.4)           | —                                     | —                                         |
| Czarnecki et al. 2020 38 | 12                       | 268/2547 (10.5)          | —                                     | —                                         |
| Dodson et al. 2017 21  | 1                        | 201/18,568 (1.1)         | —                                     | —                                         |
| Durand et al. 2017 32  | 27.2                      | 172/546 (31.5)*          | —                                     | —                                         |
| Forcillo et al. 2017 33 | —                        | —                       | —                                     | —                                         |
| Guedeney et al. 2019 34 | 12                       | 145/1339 (12.9)          | 22/99 (22.2)                          | (12)                                      |
| Kolte et al. 2017 35   | —                        | —                       | 109/2188 (5)                          | —                                         |
| Nombela-Franco et al. 2015 36 | 24               | 150/720 (20.8)*              | 35/115 (30.2)*                         | 106/605 (19.2)*                           |
| Sanchez et al. 2020 37 | 1                        | 12/616 (1.9)             | —                                     | —                                         |

Values are n/N (%), unless otherwise indicated.
* Calculated from study data.

Figure 2. The most consistently identified predictors for early and late readmission post-transcatheter aortic valve implantation. Elixhauser indicates a comorbidity among those used to determine the Elixhauser Comorbidity Index.
allowing them to follow high-risk patients more closely, which may reduce rehospitalization risk. Moreover, future projects may focus on developing and evaluating interventions to reduce readmission rates among the high-risk cohort. Decreased post-TAVI readmission rates may benefit both patients—through reduced risk for mortality and morbidity—and the healthcare system—through reduced costs from rehospitalizations. In the context of heart failure, post-discharge remote monitoring has proven effective at identifying early health deterioration, allowing for prompt intervention to prevent rehospitalization. As part of our future research, we plan to apply this strategy to TAVI patients at high risk for readmission at our centre.

Limitations

Our study findings should be evaluated in the context of several limitations. First, we did not explore studies published prior to 2015. Although this strategy could have resulted in oversight of relevant studies, we believe this to be unlikely given that our initial literature search found that the earliest relevant paper was published in 2015. Additionally, by restricting our search to this timeframe, our results are more in line with current TAVI practices and patient populations, enhancing their generalizability in the modern era. And second, our systematic review study design is limited in that it does not provide a summary estimate for our primary or secondary outcomes, as would have been possible with a meta-analysis design. We deemed a qualitative review to be more appropriate given the substantial heterogeneity among studies with regard to populations and reporting of outcome data.

Conclusion

This review demonstrates that 30-day and 1-year readmission rates post-TAVI are high, and that increased mortality is associated with readmission. In addition, it identifies the most common risk factors for both 30-day and 1-year hospital readmission. The results of this study can be used to identify patients at high-risk for hospital readmission post-TAVI. Tailored strategies can be developed accordingly to reduce readmission rates in high-risk cohorts.

Funding Sources

H.W. is supported by a Canada Research Chair in Structural Heart Disease Policy and Outcomes.

Disclosures

The authors have no conflicts of interest to disclose.

References

1. Asgar AW, Ouzounian M, Adams C, et al. 2019 Canadian Cardiovascular Society position statement for transcatheter aortic valve implantation. Can J Cardiol 2019;35:1437-48.

2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695-705.

3. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016;374:1609-20.

4. Panaich SS, Arora S, Patel N, et al. Etiologies and predictors of 30-day readmission and in-hospital mortality during primary and readmission after transcatheter aortic valve implantation. Am J Cardiol 2016;118:1705-11.

5. Nombela-Franco L, del Trigo M, Morrison-Polo G, et al. Incidence, causes, and predictors of early (< f = 30 days) and late unplanned hospital readmissions after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2015;8:1748-57.

6. Centers for Medicare & Medicaid Services. Hospital readmissions reduction program (HRRP). 2020. Available at: https://go.cms.gov/3AlAumc. Accessed October 16, 2020.

7. Holmes DR Jr, Brennan JM, Rumsfeld JS, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA 2015;313:1019-28.

8. Franzone A, Pilgrim T, Arnold N, et al. Rates and predictors of hospital readmission after transcatheter aortic valve implantation. Eur Heart J 2017;38:2211-7.

9. Friedman B, Basu J. The rate and cost of hospital readmissions for preventable conditions. Med Care Res Rev 2004;61:225-40.

10. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15.

11. Veritas Health Innovation. Covidence systematic review software. Available at: www.covidence.org. Accessed March 22, 2021.

12. Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data. Med Care 1998;36:8-27.

13. Arai T, Yashima F, Yanagisawa R, et al. Hospital readmission following transcatheter aortic valve implantation in the real world. Int J Cardiol 2018;269:56-60.

14. Kolte D, Khera S, Sardar MR, et al. Thirty-day readmissions after transcatheter aortic valve replacement in the United States: insights from the nationwide readmissions database. Circ Cardiovasc Interv 2017;10:e00472.

15. Czarnecki A, Qiu F, Henning KA, et al. Comparison of 1-year pre- and post-transcatheter aortic valve replacement hospitalization rates: a population-based cohort study. Can J Cardiol 2020;36:1616-23.

16. Auffret V, Bakhti A, Leurent G, et al. Determinants and impact of heart failure readmission following transcatheter aortic valve replacement. Circ Cardiovasc Interv 2020;13:e008959.

17. Durand E, Doutriaux M, Bettinger N, et al. Incidence, prognostic impact, and predictive factors of readmission for heart failure after transcatheter aortic valve replacement. JACC Cardiovasc Interv 2017;10:2426-36.

18. Fortillo J, Condado JF, Binongo JN, et al. Readmission rates after transcatheter aortic valve replacement in high- and extreme-risk patients with severe aortic stenosis. J Thorac Cardiovasc Surg 2017;154:445-52.

19. Guenedey P, Huchet F, Manigold T, et al. Incidence of, risk factors for and impact of readmission for heart failure after successful transcatheter aortic valve implantation. Arch Cardiovasc Dis 2019;112:765-72.

20. Allaudeen N, Vidyarthi A, Maselli J, et al. Redefining readmission risk factors for general medicine patients. J Hosp Med 2011;6:54-60.

21. Goldsweg A, Aronow HD. Identifying patients likely to be readmitted after transcatheter aortic valve replacement. Heart 2020;106:256-60,
22. Li YM, Mei FY, Yeo YJ, et al. Causes and predictors of readmission after transcatheter aortic valve implantation: a meta-analysis and systematic review. Herz 2021;46:1-8.

23. Dodson JA, Williams MR, Cohen DJ, et al. Hospital practice of direct-home discharge and 30-day readmission after transcatheter aortic valve replacement in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) registry. J Am Heart Assoc 2017;6:e006127.

24. Doshi R, Taha M, Dave M, et al. Sex differences in 30-day readmission rates, etiology, and predictors after transcatheter aortic valve replacement. Indian Heart J 2019;71:291-6.

25. Abdel-Wahab M, Neumann FJ, Mehilli J, et al. 1-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: results from the CHOICE randomized clinical trial. J Am Coll Cardiol 2015;66:791-800.

26. Reardon MJ, Feldman TE, Meduri CU, et al. Two-year outcomes after transcatheter aortic valve replacement with mechanical vs self-expanding valves: the REPRISE III randomized clinical trial. JAMA Cardiol 2019;4:223-9.

27. Ware P, Ross HJ, Caffaz JA, et al. Outcomes of a heart failure tele-monitoring program implemented as the standard of care in an outpatient heart function clinic: pretest-posttest pragmatic study. J Med Internet Res 2020;22:e16538.

28. Czarnecki A, Austin PC, Fremes SE, et al. Association between transitional care factors and hospital readmission after transcatheter aortic valve replacement: a retrospective observational cohort study. BMC Cardiovasc Disord 2019;19:23.

29. Elbaz-Greener G, Qiu F, Webb JG, et al. Procalcitonin levels and predictors for long-term clinical outcomes in intermediate-risk patients: an analysis from the PARTNER II trial. Eur Heart J 2019;40:2218-27.

30. Ware P, Ross HJ, Caffaz JA, et al. Outcomes of a heart failure tele-monitoring program implemented as the standard of care in an outpatient heart function clinic: pretest-posttest pragmatic study. J Med Internet Res 2020;22:e16538.

31. Tripathi B, Nerusu LA, Sawant AC, et al. Transcatheter aortic valve implantation readmissions in the current era (from the National Readmission Database). Am J Cardiol 2020;127:120-7.

32. Yerasi C, Tripathi B, Wang Y, et al. Impact of frailty on mortality, and predictors of readmission after transcatheter aortic valve replacement. Herz 2021;46:1-8.

33. Tripathi B, Nerusu LA, Sawant AC, et al. Transcatheter aortic valve implantation 30-day readmission rates: a meta-analysis and systematic review: a nationwide analysis from the USA. Eur Heart J Qual Care Clin Outcomes 2022;8:135-42.

34. Johansson M, Nozohoor S, Bjursten H, et al. Late survival and heart failure after transcatheter aortic valve implantation. Asian Cardiovasc Thorac Ann 2016;24:318-25.

35. Malik AH, Vandrapalli S, Zaid S, et al. Impact of frailty on mortality, readmissions, and resource utilization after TAVI. Am J Cardiol 2020;127:120-7.

36. Saji M, Higuchi R, Tobaru T, et al. Impact of frailty markers for unplanned hospital readmission following transcatheter aortic valve implantation. Circ J 2018;82:2191-8.

37. Deharo P, Bisson A, Herbert J, et al. Impact of Sapien 3 balloon-expandable versus Evolut R self-expandable transcatheter aortic valve implantation in patients with aortic stenosis: data from a nationwide analysis. Circulation 2020;141:260-8.
transcatheter aortic valve replacement in the PARTNER Trial. Ann Thorac Surg 2016;102:1172-80.

55. Tirado-Conte G, Freitas-Ferraz AB, Nombela-Franco L, et al. Incidence, causes, and impact of in-hospital infections after transcatheter aortic valve implantation. Am J Cardiol 2016;118:403-9.

56. O’Leary JM, Clavel MA, Chen S, et al. Association of natriuretic peptide levels after transcatheter aortic valve replacement with subsequent clinical outcomes. JAMA Cardiol 2020;5:1113-23.

57. Lemor A, Hernandez G, Bavishi C, et al. Endovascular versus transapical transcatheter aortic valve replacement: in-hospital mortality, hospital outcomes, and 30-day readmission. A propensity score-matched analysis. Crit Pathw Cardiol 2019;18:102-7.

58. Inohara T, Manandhar P, Kosinski AS, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA 2018;320:2231-41.

59. Herrmann HC, Daneshvar SA, Fonarow GC, et al. Prosthesis-patient mismatch in patients undergoing transcatheter aortic valve replacement: from the STS/ACC TVT Registry. J Am Coll Cardiol 2018;72:2701-11.

60. Emami S, Rudasill S, Bellamkonda N, et al. Impact of malnutrition on outcomes following transcatheter aortic valve implantation (from a national cohort). Am J Cardiol 2020;125:1096-101.

61. Arora S, Hendrickson MJ, Strasse PD, et al. Trends in costs and risk factors of 30-day readmissions for transcatheter aortic valve implantation. Am J Cardiol 2020;137:89-96.

62. Arora S, Strasse PD, Hendrickson MJ, et al. Cause and risk factors for readmissions after transcatheter aortic valve replacement. Eur Heart J 2020;41:1948.

63. Freitas-Ferraz AB, Lerakis S, Barbosa Ribeiro H, et al. Mitral regurgitation in low-flow, low-gradient aortic stenosis patients undergoing TAVR: insights from the TOPAS-TAVI Registry. JACC Cardiovasc Interv 2020;13:567-79.

64. McCarthy FH, Vemulapalli S, Li Z, et al. Association of tricuspid regurgitation with transcatheter aortic valve replacement outcomes: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Ann Thorac Surg 2018;105:1121-8.

65. Miura M, Yamaji K, Shirai S, et al. Clinical impact of preprocedural moderate or severe mitral regurgitation on outcomes after transcatheter aortic valve replacement. Can J Cardiol 2020;36:1112-20.

Supplementary Material

To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.cjco.2022.05.007.